JMPWA
KPTI icon

JP Morgan Private Wealth Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-801
Closed -$66K – 1968
2022
Q3 		$66K Sell
801
-22
-3% -$1.64K ﹤0.01% 1888
2022
Q2 		$56K Sell
823
-33
-4% -$3.03K ﹤0.01% 1894
2022
Q1 		$95K Sell
856
-256
-23% -$31.9K ﹤0.01% 1951
2021
Q4 		$107K Sell
1,112
-42
-4% -$4.19K ﹤0.01% 1940
2021
Q3 		$101K Sell
1,154
-343
-23% -$35.6K ﹤0.01% 1897
2021
Q2 		$232K Buy
1,497
+320
+27% +$46.4K ﹤0.01% 1784
2021
Q1 		$186K Sell
1,177
-24
-2% -$5.06K ﹤0.01% 1701
2020
Q4 		$279K Sell
1,201
-258
-18% -$59.8K ﹤0.01% 1529
2020
Q3 		$320K Buy
1,459
+467
+47% +$114K ﹤0.01% 1337
2020
Q2 		$282K Buy
992
+172
+21% +$50.9K ﹤0.01% 1329
2020
Q1 		$236K Buy
+820
New +$226K ﹤0.01% 1230

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Private Wealth Advisors's KPTI Position: Q4 2022 in Review

JP Morgan Private Wealth Advisors sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 801 shares — an estimated $66K sold.

JP Morgan Private Wealth Advisors first reported a position in KPTI in Q1 2020 and held it in 11 quarters. The position peaked at $320K in Q3 2020. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • JP Morgan Private Wealth Advisors reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 801 Karyopharm Therapeutics shares in Q4 2022, an estimated $66K.
  • JP Morgan Private Wealth Advisors first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 11 quarters.
  • JP Morgan Private Wealth Advisors's Karyopharm Therapeutics position peaked at $320K in Q3 2020.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.